Combination Antibody Market by 2024
Create successful ePaper yourself
Turn your PDF publications into a flip-book with our unique Google optimized e-Paper software.
P e r s i s t e n c e M a r k e t R e s e a r c h<br />
Demand for combination antibody therapy will be high for breast cancer and lung cancer<br />
treatment on the basis of applications. The lung cancer segment is anticipated to expand at a<br />
value CAGR of 17.1% during the assessment period.<br />
By end user, hospitals are expected to be the largest segment of the market throughout the<br />
forecast period. In 2015, the segment was valued at US$ 26,906.5 Million, which is expected to<br />
surpass US$ 95,885 Million <strong>by</strong> <strong>2024</strong> end, reflecting a CAGR of 15.2%.<br />
From a regional perspective, North America will continue to be the leading market for<br />
combination antibody therapy over the forecast period. In addition, the region is set to witness a<br />
CAGR of over 13% in terms of value. Whereas, APAC is expected to reflect the fastest growth of<br />
the market during the forecast period in terms of value. Further, the market in the region is<br />
estimated to witness a 3.4X growth in terms of sales over <strong>2024</strong> owing to increasing prevalence<br />
of carcinogenic disorders in APAC.<br />
Request to View Tables of Content @ http://www.persistencemarketresearch.com/marketresearch/combination-antibody-therapy-market/toc<br />
Key participants functioning in the global market for combination antibody therapy include Roche<br />
Holdings AG, Amgen Incorporated, Novartis AG, Celgene Corporation, Biogen Inc., Seattle<br />
Genetics Inc., Genmab A/S, Bristol-Myers Squibb Company, Eli-Lilliy and Company and Sanofi.<br />
To Buy Full Report for a Single User @<br />
http://www.persistencemarketresearch.com/checkout/11740<br />
About Us:<br />
<strong>Combination</strong> <strong>Antibody</strong> Therapy <strong>Market</strong> <strong>2024</strong>
Change language